Compare · ACXP vs SMMT
ACXP vs SMMT
Side-by-side comparison of Acurx Pharmaceuticals Inc. (ACXP) and Summit Therapeutics Inc. (SMMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACXP and SMMT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SMMT is the larger of the two at $13.31B, about 2324.1x ACXP ($5.7M).
- Over the past year, ACXP is down 80.0% and SMMT is down 16.1% - SMMT leads by 63.9 points.
- SMMT has been more active in the news (11 items in the past 4 weeks vs 5 for ACXP).
- SMMT has more recent analyst coverage (25 ratings vs 1 for ACXP).
- Company
- Acurx Pharmaceuticals Inc.
- Summit Therapeutics Inc.
- Price
- -
- -
- Market cap
- $5.7M
- $13.31B
- 1M return
- -16.53%
- +4.43%
- 1Y return
- -80.02%
- -16.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 5
- 11
- Recent ratings
- 1
- 25
Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest ACXP
- Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
- SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.
- SEC Form 8-K filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
- Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
- SEC Form 8-K filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
- SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.
- SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.
- Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
Latest SMMT
- Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Summit Therapeutics Inc.
- SEC Form 10-Q filed by Summit Therapeutics Inc.
- Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
- Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
- Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
- Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
- Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
- Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma